RFL (Rafael Holdings, Inc. Class B Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by RFL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-31 | HOWARD S JONAS | Exec Chairman, CEO & President | A | — | — |
| 2026-06-23 | David Polinsky | Chief Financial Officer | F | — | — |
| 2026-06-16 | HOWARD S JONAS | Exec Chairman, CEO & President | MIXED | — | — |
| 2026-03-24 | David Polinsky | Chief Financial Officer | F | — | — |
| 2026-03-17 | HOWARD S JONAS | Exec Chairman, CEO & President | F | — | — |
| 2026-01-30 | Markus Sieger | Director | A | — | — |
| 2026-01-29 | MICHAEL J WEISS | Director | A | — | — |
| 2026-01-29 | MARK N STEIN | Director | A | — | — |
| 2026-01-29 | ALAN GRAYSON | Director | A | — | — |
| 2026-01-15 | David Polinsky | Chief Financial Officer | MIXED | — | — |
| 2026-01-15 | HOWARD S JONAS | Exec Chairman, CEO & President | A | — | — |
| 2025-12-23 | David Polinsky | Chief Financial Officer | F | — | — |
| 2025-12-16 | HOWARD S JONAS | Exec Chairman, CEO & President | F | — | — |
| 2025-03-25 | David Polinsky | Chief Financial Officer | F | — | — |
| 2025-03-25 | WILLIAM CONKLING | Chief Executive Officer | F | — | — |
| 2025-01-15 | JOHN GOLDBERG | CHIEF MEDICAL OFFICER | A | — | — |
| 2025-01-15 | David Polinsky | Chief Financial Officer | A | — | — |
| 2025-01-15 | WILLIAM CONKLING | Chief Executive Officer | A | — | — |
| 2025-01-08 | STEPHEN M GREENBERG | Director | A | — | — |
| 2025-01-08 | MARK N STEIN | Director | A | — | — |
| 2025-01-08 | MICHAEL J WEISS | Director | A | — | — |
| 2024-12-23 | David Polinsky | Chief Financial Officer | F | — | — |
| 2024-12-23 | WILLIAM CONKLING | Chief Executive Officer | F | — | — |
| 2024-10-29 | WILLIAM CONKLING | Chief Executive Officer | F | — | — |
| 2024-10-29 | David Polinsky | Chief Financial Officer | F | — | — |
| 2024-09-24 | WILLIAM CONKLING | Chief Executive Officer | F | — | — |
| 2024-09-24 | David Polinsky | Chief Financial Officer | F | — | — |
| 2024-07-26 | HOWARD S JONAS | Executive Chairman | J | — | — |
| 2024-06-28 | HOWARD S JONAS | Executive Chairman | J | — | — |
| 2024-06-25 | WILLIAM CONKLING | Chief Executive Officer | F | — | — |
| 2024-06-25 | David Polinsky | Chief Financial Officer | F | — | — |
| 2024-06-17 | HOWARD S JONAS | Executive Chairman | MIXED | — | — |
| 2024-04-08 | HOWARD S JONAS | Executive Chairman | J | — | — |
| 2024-03-25 | WILLIAM CONKLING | Chief Executive Officer | F | — | — |
| 2024-03-25 | David Polinsky | Chief Financial Officer | F | — | — |
| 2024-02-01 | HOWARD S JONAS | Executive Chairman | J | — | — |
| 2024-01-18 | JOHN GOLDBERG | CHIEF MEDICAL OFFICER | A | — | — |
| 2024-01-08 | Mark Anthony McCamish | Director | A | — | — |
| 2024-01-08 | STEPHEN M GREENBERG | Director | A | — | — |
| 2024-01-08 | MICHAEL J WEISS | Director | A | — | — |
| 2023-12-26 | WILLIAM CONKLING | Chief Executive Officer | F | — | — |
| 2023-12-26 | David Polinsky | Chief Financial Officer | F | — | — |
| 2023-10-26 | David Polinsky | Chief Financial Officer | A | — | — |
| 2023-10-26 | WILLIAM CONKLING | Chief Executive Officer | A | — | — |
| 2023-09-26 | David Polinsky | Chief Financial Officer | F | — | — |
| 2023-09-22 | WILLIAM CONKLING | Chief Executive Officer | F | — | — |
| 2023-08-30 | HOWARD S JONAS | Executive Chairman | A | — | — |
| 2023-08-01 | HOWARD S JONAS | Executive Chairman | J | — | — |
| 2023-06-22 | WILLIAM CONKLING | Chief Executive Officer | F | — | — |
| 2023-03-23 | WILLIAM CONKLING | Chief Executive Officer | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,225,806 | — |
| — | Exec Chairman, CEO & President | 610,850 | — |
| — | Chief Executive Officer | 537,001 | — |
| — | CFO & President | 335,175 | — |
| — | Chief Financial Officer | 299,111 | — |
| — | Director | 219,710 | — |
| — | Director | 141,861 | — |
| — | President | 127,693 | — |
| — | Director | 102,491 | — |
| — | Director | 60,241 | — |
| — | Director | 50,845 | — |
| — | CHIEF MEDICAL OFFICER | 50,000 | — |
| — | Director | 47,295 | — |
| — | — | 22,625 | — |
| — | Director | 6,562 | — |
| — | Director | 5,412 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RFL quote page; the site-wide leaderboard is on the insider transactions hub.